Vol. 14 (04) pp. 900-904 DOI: 10.21474/IJAR01/23261

PCR AFTER NEOADJUVANT CHEMOTHERAPY AND SURVIVAL IN LOCALIZED BLADDER CANCER: A MOROCCAN EXPERIENCE

, , , , , , , , , and
  • Department of Medical Oncology, Hassan II University Hospital, Fez, Morocco.
6 Downloads 39 Views
Crossref

Download Full Paper (PDF)

Abstract

Background: Neoadjuvant cisplatin based chemotherapy followed by radical cystectomy is the standard of care for localized muscle invasive bladder cancer (MIBC). Pathological complete response (pCR) is a strong prognostic marker for survival. However, real world data from low and middle income countries remain limited. Objective: To evaluate operability and pCR rates after neoadjuvant chemotherapy and their correlation with overall survival (OS) and relapse free survival (RFS) in Moroccan patients with MIBC. Methods: We conducted a retrospective, single center study at the Medical Oncology Department of CHU Hassan II Fez, including 65 patients with MIBC who received at least 3 cycles of cisplatin based neoadjuvant chemotherapy between January 2018 and December 2023.

Keywords

Article Analytics

How to Cite This Article

Hafssa El Hilali et, al (2026); PCR AFTER NEOADJUVANT CHEMOTHERAPY AND SURVIVAL IN LOCALIZED BLADDER CANCER: A MOROCCAN EXPERIENCE, Int. J. of Adv. Res., 14 (04), 900-904, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/23261

Corresponding Author

Hafssa El Hilali
Department of Medical Oncology, Hassan II University Hospital, Fez, Morocco.
Morocco
Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.